

# Ortho Clinical Diagnostics

## Ortho Clinical Diagnostics to Unveil Next-Generation Analyzer at AACC and Share Research on IVDs for application in Cardiology, Infectious Disease and Endocrinology

July 30, 2018

**Ortho will showcase its new VITROS® XT 7600 Integrated System and demonstrate its commitment to expanded menu offerings and improved patient care**

Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, today announced it will officially unveil the VITROS® XT 7600 Integrated System\*, now available in numerous countries that accept CE Mark, at the 2018 American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo. It also will present seven scientific posters highlighting performance of assays that are part of its offerings for sepsis, Chagas, diabetes and other conditions. In addition to the VITROS® XT 7600\*, Ortho will display additional clinical lab and immunohematology analyzers and other solutions in its booth (No. 612). The conference will be held July 29-Aug. 2 at the McCormick Place convention center in Chicago.

"Ortho is committed to innovation that helps our customers achieve their goals of enhancing medical value while increasing efficiency," said Robert Yates, chief operating officer for Ortho. "We're delighted to officially reveal at AACC Ortho's VITROS® XT 7600\*, which introduces fundamental change to the way labs operate, and to present insightful posters in the areas of cardiology, infectious disease and endocrinology."

Ortho will display the following posters at the conference:

- **Performance Evaluation of the VITROS® hs Troponin I Assay\* on the VITROS® 5600 Integrated and VITROS® 3600 and ECi/ECiQ Immunodiagnostic Systems**  
Poster Session: July 31 from 9:30 a.m. to 5 p.m.  
Author Presentation: 12:30 to 1:30 p.m.  
Presenter: Shari Jackson, senior scientist, Ortho Clinical Diagnostics
- **An Evaluation of Performance of the VITROS® Immunodiagnostic Products Anti-T. cruzi (Chagas) Assay\***  
Poster Session: Aug. 1 from 9:30 a.m. to 5 p.m.  
Author Presentation: 12:30 to 1:30 p.m.  
Presenter: Paul Contestable, principal scientist and technical leader, Ortho Clinical Diagnostics
- **Method Comparison of the VITROS® Immunodiagnostic Products Anti-T. cruzi (Chagas) Assay\* to the Ortho® T. cruzi ELISA Test System**  
Poster Session: Aug. 1 from 9:30 a.m. to 5 p.m.  
Author Presentation: 12:30 to 1:30 p.m.  
Presenter: Paul Contestable, principal scientist and technical leader, Ortho Clinical Diagnostics
- **Performance Evaluation of the VITROS® Immunodiagnostic Products B-R-A-H-M-S PCT Assay\* on the VITROS 3600 Immunodiagnostic Systems**  
Poster Session: Aug. 1 from 9:30 a.m. to 5 p.m.  
Author Presentation: 12:30 to 1:30 p.m.  
Presenter: Godwin Ogbonna, PhD., FACB, principal scientist, Research & Development, Ortho Clinical Diagnostics
- **Development of the Novel and New Multi-Test VITROS® XT Chemistry Products Slides\***  
Poster Session: Aug. 1 from 9:30 a.m. to 5 p.m.  
Author Presentation: 12:30 p.m. to 1:30 p.m.  
Presenter: Ted DiMagno, PhD., principal scientist, Ortho Clinical Diagnostics
- **Performance of the ARK Diagnostics, Inc., ARKTM Methotrexate Assay on the VITROS® 4600 Chemistry System and the VITROS® 5600 Integrated System**  
Poster Session: Aug. 1 from 9:30 a.m. to 5 p.m.  
Author Presentation: 12:30 p.m. to 1:30 p.m.  
Presenter: Karen Ackles, senior scientist, assay R&D, Ortho Clinical Diagnostics
- **Performance of the Sentinel Diagnostics C-Reactive Protein Ultra (MP)® Assay on the VITROS® 4600 Chemistry System and the VITROS® 5600 Integrated System**  
Poster Session: Aug. 1 from 9:30 a.m. to 5 p.m.  
Author Presentation: 12:30 p.m. to 1:30 p.m.  
Presenter: Gary Snodgrass, principal scientist, Ortho Clinical Diagnostics

In addition to its seven posters, Ortho collaborated with partners on the following research that will be presented at AACC:

- **Performance of Diazyme Lp(a) Assay Assay on the VITROS® 4600 Chemistry System and the VITROS® 5600 Integrated System**
- **Performance of the Diazyme Laboratories Inc. Glycated Serum Protein Assay on the VITROS® 4600 Chemistry System and the VITROS® 5600 Integrated System**
- **Performance of a five member panel of Bio-Rad Laboratories HIV Quality Controls on the Ortho VITROS® HIV Combo assay**

Ortho's latest analyzer to receive CE Mark, the VITROS® XT 7600 Integrated System\*, which will be on display in Ortho's booth, combines proprietary dry slide technology with sophisticated digital imaging capabilities and the potential to perform two separate lab tests simultaneously, introducing digital chemistry to clinical lab management.

Additional products on display at Ortho's booth include VITROS® 3600 Immunodiagnostic Systems, VITROS® 4600 Chemistry Systems, VITROS® 5600 Integrated Systems, VITROS® Automation Solutions and immunohematology analyzers, ORTHO VISION® and ORTHO VISION® Max.

At the booth, visitors can explore Ortho's commitment to innovation firsthand with the virtual reality experience LabBuilder, which allows users to reimagine what's possible by creating a digital lab that fits their needs. Attendees can learn more about the new VITROS® XT 7600\* and Ortho's dedication to enhanced laboratory operations and improved patient experience with product demonstrations, which will occur in the booth every 45 minutes.

#### **About Ortho Clinical Diagnostics**

Ortho Clinical Diagnostics is a global leader of in vitro diagnostics serving the clinical laboratory and immunohematology communities. Across hospitals, hospital networks, blood banks and labs in more than 125 countries and territories, Ortho's high-quality products and services enable health care professionals to make better-informed treatment decisions. For the immunohematology community, Ortho's blood typing products help ensure every patient receives blood that is safe, the right type and the right unit. Ortho brings sophisticated testing technologies, automation, information management and interpretation tools to clinical laboratories around the world to help them run more efficiently and effectively and improve patient care. Ortho's purpose is to improve and save lives with diagnostics, and it does that by reimagining what's possible. This is what has defined Ortho for more than 75 years, and it's what drives Ortho forward.

\* In Development – Not approved or cleared in the United States

Product availability subject to local regulatory requirements

© Ortho Clinical Diagnostics 2018, PR-04171

#### **Press contact:**

For media inquiries please contact

Ortho Media Relations  
Ortho Clinical Diagnostics  
[media@orthoclinicaldiagnostics.com](mailto:media@orthoclinicaldiagnostics.com)  
(+1) 908 704 8256